Advancing muscle biology, Robert Blum, Pres. & CEO, & Fady Malik, EVP, Research & Dev., Cytokinetics
Synopsis: Robert Blum and Fady Malik are the President & CEO and EVP, Research and Development, respectively, of Cytokinetics, a late-stage biopharmaceutical company committed to developing potenti...
30 Aug 202329min
Transforming the treatment of neuromuscular diseases, James McArthur, CEO, PepGen
Synopsis: James McArthur is the CEO of PepGen, a biotech company creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious ge...
23 Aug 202328min
Conquering new frontiers in cell therapy, Paul Lammers, CEO, Triumvira Immunologics
Synopsis: Paul Lammers, M.D., is the CEO of Triumvira Immunologics, a clinical-stage immuno-oncology company developing unique, targeted autologous and allogeneic T cell therapeutics that co-opt the...
16 Aug 202333min
Next-gen immunotherapies for cancer, Andrew Scharenberg, Co-founder & CEO, Umoja Biopharma
Synopsis: Andrew Scharenberg is the Co-founder and CEO of Umoja Biopharma, a company pioneering the future of immunotherapy by reprogramming T cells in vivo. Umoja’s groundbreaking integrated platfor...
9 Aug 202332min
Transforming medicine through non-viral gene therapy, Theresa Heah, CEO, Intergalactic Tx
Synopsis: Theresa Heah, M.D., is the CEO of Intergalactic Therapeutics. Intergalactic is overcoming the limitations of viral-based gene therapy and developing a best-in-class non-viral alternative. I...
2 Aug 202319min
Transforming diseased cells into coordinators of cure, Volker Herrmann, President & CEO, Sonata Tx
Synopsis: Volker Herrmann is the President and CEO of Sonata Therapeutics, a Flagship Pioneering company revolutionizing the world’s understanding of the cellular microenvironment and its importance...
26 Juli 202334min
Breaking barriers in rare genetic mitochondrial diseases, Greg Flesher, Pres. & CEO, Reneo
Synopsis: Greg Flesher is the President and CEO of Reneo Pharmaceuticals, a clinical-stage pharmaceutical company focused on the development of therapies for patients with rare genetic mitochondrial...
19 Juli 202327min
Correcting abnormal gene expression in oncology, Adrian Gottschalk, Pres. & CEO, Foghorn Tx
Synopsis: Adrian Gottschalk is the president and CEO of Foghorn Therapeutics, a clinical-stage biotechnology company pioneering a new class of medicines that treat cancers and other serious diseases...
12 Juli 202331min
